Description
Vivimed Labs Ltd. equity shares will be moved from their current group to 'B' group effective December 26, 2025.
Summary
BSE has announced that equity shares of Vivimed Labs Ltd. (Scrip Code: 532660) will be transferred to ‘B’ group effective December 26, 2025. Trading members have been notified of this group reclassification.
Key Points
- Vivimed Labs Ltd. equity shares (Scrip Code: 532660) will be included under ‘B’ group
- Change is effective from December 26, 2025
- Notice issued to all trading members
- Contact person: Ms. Kinjal More (Cell: +91-7304278788) for clarifications
Regulatory Changes
The equity shares will move to ‘B’ group, which typically indicates a change in trading surveillance or liquidity parameters as per BSE’s group classification system.
Compliance Requirements
Trading members must:
- Take note of the group change for Vivimed Labs Ltd.
- Update their systems and trading parameters accordingly
- Contact BSE Listing Compliance team for any clarifications needed before the effective date
Important Dates
- Notice Date: December 18, 2025
- Effective Date: December 26, 2025
Impact Assessment
The reclassification to ‘B’ group may impact trading parameters, margin requirements, and surveillance measures for Vivimed Labs equity shares. Trading members and investors should be aware of any changes in trading conditions that may apply under the new group classification. The move to ‘B’ group typically indicates enhanced surveillance or changed liquidity conditions.
Impact Justification
Group change to 'B' group affects trading parameters and surveillance for Vivimed Labs equity shares, impacting trading members and investors.